Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GNRHR | P30968 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RGS4 | P49798 | 3/20 | 0.38 |
| ▸ | RGS8 | P57771 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.37 |
| ▸ | RGS16 | O15492 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769603 | 0.86 | DCTPP1 (0.46) | KMT2AMAPTRGS4P2RX3MAPK1 | |
| SCHEMBL4769688 | 0.86 | PDE4A (0.40) | POLBGNRHRKMT2ACYP3A4P2RX3 | |
| SCHEMBL4770944 | 0.83 | ADORA2A (0.39) | POLBGNRHRLMNAMAPTRGS4 | |
| SCHEMBL4767472 | 0.83 | POLB (0.46) | POLBTP53KMT2ASOS1LMNA | |
| SCHEMBL4765718 | 0.81 | PDE4D (0.46) | POLBGNRHRTP53KMT2ASOS1 | |
| SCHEMBL4766297 | 0.81 | HSPD1 (0.36) | POLBGNRHRKMT2AALDH1A1HSD17B10 | |
| SCHEMBL4763645 | 0.78 | SIRT1 (0.40) | GNRHRKMT2ALMNAMAPTRGS4 | |
| SCHEMBL4767325 | 0.77 | P2RX3 (0.54) | GNRHRTP53KMT2ACYP3A4CYP2C19 | |
| SCHEMBL4765585 | 0.76 | MAPT (0.44) | GNRHRKMT2ALMNAMAPTMAPK1 | |
| SCHEMBL4770686 | 0.75 | DCTPP1 (0.51) | KMT2AMAPTRGS4MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | POLB 1001/4885GNRHR 1042/4885TP53 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.